The University of Chicago Header Logo

Connection

Hans Schreiber to Humans

This is a "connection" page, showing publications Hans Schreiber has written about Humans.
Connection Strength

0.322
  1. Criteria to make animal studies more relevant to treating human cancer. Curr Opin Immunol. 2022 02; 74:25-31.
    View in: PubMed
    Score: 0.027
  2. Fibroblasts: Dangerous travel companions. J Exp Med. 2019 03 04; 216(3):479-481.
    View in: PubMed
    Score: 0.023
  3. Editorial overview: tumour immunology. Curr Opin Immunol. 2015 Apr; 33:ix-xi.
    View in: PubMed
    Score: 0.017
  4. Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol. 2015 Apr; 33:112-9.
    View in: PubMed
    Score: 0.017
  5. Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell. 2013 Apr 15; 23(4):516-26.
    View in: PubMed
    Score: 0.015
  6. Spleen cells from young but not old immunized mice eradicate large established cancers. Clin Cancer Res. 2012 May 01; 18(9):2526-33.
    View in: PubMed
    Score: 0.014
  7. Targeting stroma to treat cancers. Semin Cancer Biol. 2012 Feb; 22(1):41-9.
    View in: PubMed
    Score: 0.014
  8. Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes. Cancer Immun. 2011 Jun 30; 11:2.
    View in: PubMed
    Score: 0.013
  9. Tumor-specific immune responses. Semin Immunol. 2008 Oct; 20(5):265-6.
    View in: PubMed
    Score: 0.011
  10. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest. 2008 Nov; 118(11):3574-81.
    View in: PubMed
    Score: 0.011
  11. Specificity in cancer immunotherapy. Semin Immunol. 2008 Oct; 20(5):276-85.
    View in: PubMed
    Score: 0.011
  12. Cancer. Quo vadis, specificity? Science. 2008 Jan 11; 319(5860):164-5.
    View in: PubMed
    Score: 0.010
  13. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol. 2006 Apr; 18(2):226-31.
    View in: PubMed
    Score: 0.009
  14. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004 Dec; 14(6):433-9.
    View in: PubMed
    Score: 0.008
  15. Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-gamma pathway but not IL-12 or IL-18. J Immunol. 2004 Mar 01; 172(5):3243-51.
    View in: PubMed
    Score: 0.008
  16. Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. Curr Opin Immunol. 2003 Dec; 15(6):725-30.
    View in: PubMed
    Score: 0.008
  17. Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model. J Immunother Cancer. 2023 05; 11(5).
    View in: PubMed
    Score: 0.008
  18. Immunodominance and tumor escape. Semin Cancer Biol. 2002 Feb; 12(1):25-31.
    View in: PubMed
    Score: 0.007
  19. Immunological enhancement of primary tumor development and its prevention. Semin Cancer Biol. 2000 Oct; 10(5):351-7.
    View in: PubMed
    Score: 0.006
  20. Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides. Proc Natl Acad Sci U S A. 2020 06 30; 117(26):15148-15159.
    View in: PubMed
    Score: 0.006
  21. LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor ß Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models. Hum Gene Ther. 2020 08; 31(15-16):863-880.
    View in: PubMed
    Score: 0.006
  22. Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. JCI Insight. 2019 11 01; 4(21).
    View in: PubMed
    Score: 0.006
  23. Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells. Clin Cancer Res. 2020 02 01; 26(3):679-689.
    View in: PubMed
    Score: 0.006
  24. A strategy for generating cancer-specific monoclonal antibodies to aberrant O-glycoproteins: identification of a novel dysadherin-Tn antibody. Glycobiology. 2019 04 01; 29(4):307-319.
    View in: PubMed
    Score: 0.006
  25. Unique tumor antigens redefined as mutant tumor-specific antigens. Semin Immunol. 1996 Oct; 8(5):289-93.
    View in: PubMed
    Score: 0.005
  26. Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity. 2016 06 21; 44(6):1444-54.
    View in: PubMed
    Score: 0.005
  27. Prevention of runting and cachexia by a chimeric TNF receptor-Fc protein. Clin Immunol Immunopathol. 1993 Nov; 69(2):215-22.
    View in: PubMed
    Score: 0.004
  28. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013 Oct; 14(10):1014-22.
    View in: PubMed
    Score: 0.004
  29. Footprinting of individual tumors and their variants by constitutive cytokine expression patterns. Cancer Res. 1993 May 01; 53(9):1978-81.
    View in: PubMed
    Score: 0.004
  30. IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner. Proc Natl Acad Sci U S A. 2013 May 14; 110(20):8158-63.
    View in: PubMed
    Score: 0.004
  31. Design and characterization of a protein superagonist of IL-15 fused with IL-15Ra and a high-affinity T cell receptor. Biotechnol Prog. 2012 Nov-Dec; 28(6):1588-97.
    View in: PubMed
    Score: 0.004
  32. Tumor antigens. Annu Rev Immunol. 1992; 10:617-44.
    View in: PubMed
    Score: 0.003
  33. Antibody recognition of a unique tumor-specific glycopeptide antigen. Proc Natl Acad Sci U S A. 2010 Jun 01; 107(22):10056-61.
    View in: PubMed
    Score: 0.003
  34. Tumor-specific antigens and tumor-specific mutant proteins in mouse and man. Haematol Blood Transfus. 1989; 32:284-8.
    View in: PubMed
    Score: 0.003
  35. Unique tumor-specific antigens. Annu Rev Immunol. 1988; 6:465-83.
    View in: PubMed
    Score: 0.003
  36. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol. 2007 Aug 01; 179(3):1960-8.
    View in: PubMed
    Score: 0.003
  37. Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments. Hematol Oncol Clin North Am. 2006 Jun; 20(3):567-84.
    View in: PubMed
    Score: 0.002
  38. Active immunization against cancer cells: impediments and advances. Semin Oncol. 1998 Dec; 25(6):697-706.
    View in: PubMed
    Score: 0.001
  39. Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker. Ann Surg. 1998 Mar; 227(3):372-9.
    View in: PubMed
    Score: 0.001
  40. [Immunocytologic detection of disseminated tumor cells in the peritoneal cavity and bone marrow in patients with pancreatic carcinoma]. Chirurg. 1994 Dec; 65(12):1111-5.
    View in: PubMed
    Score: 0.001
  41. Immunocytological detection of micrometastatic cells: comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients. Int J Cancer. 1994 May 01; 57(3):330-5.
    View in: PubMed
    Score: 0.001
  42. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol. 1994 Apr; 12(4):725-9.
    View in: PubMed
    Score: 0.001
  43. Antiproliferative effects exerted by recombinant human tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) on human pancreatic tumor cell lines. Pancreas. 1988; 3(2):180-8.
    View in: PubMed
    Score: 0.001
  44. [Clinical aspects and therapy of Merkel cell tumor--report of 4 personal cases and review of the literature]. Langenbecks Arch Chir. 1988; 373(3):173-81.
    View in: PubMed
    Score: 0.001
  45. [CA 12-5 in cancer of the digestive tract. A comparison with CA 19-9 and CEA in cancer of the pancreas and colon]. Dtsch Med Wochenschr. 1984 Dec 21; 109(51-52):1949-54.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.